

Grifols recognized as one of the world's most sustainable companies by Dow Jones Sustainability Index for third consecutive year

- *Grifols has been included in the Dow Jones Sustainability World Index (DJSI World) for the second consecutive year and the Dow Jones Sustainability Europe Index (DJSI Europe) for third straight year*
- *Grifols continues to rank among the five top-scoring biotechnology companies, excelling in corporate citizenship and philanthropy, climate strategy, human rights, environmental and social reporting, and marketing practices*
- *This strong positioning in the DJSI reflects Grifols' standing as a sustainability leader, on the back of recent efforts to strengthen its longstanding corporate responsibility actions in diversity and inclusion, equality and climate change*

Barcelona, Spain, December 12, 2022.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, has announced it has been included in the Dow Jones Sustainability World Index for the second consecutive year and the Dow Jones Sustainability Europe Index for the third straight year.

The company's inclusion in these two prestigious indices evidences its longstanding leadership position and commitment to transparency in environmental, social and governance (ESG) matters. Grifols ranked among the five top-scoring global leaders in its industry. This year, the Dow Jones Sustainability Index (DJSI) posted a record number of 1,728 companies assessed in 2022, an increase of 9% over last year.

The DJSI are investor-led and serve as a benchmark for investors who integrate sustainability considerations into their portfolios and seek best-in-class performance. They are considered to be among the most prestigious global indicators of corporate sustainability leadership and ESG performance thanks to the extensive number of companies assessed and the rigorous nature of the annual assessment process.

"We are once again truly honored to be included in the prestigious Dow Jones Sustainability Index as one of the world's most sustainable companies. The recognition reflects our unwavering and longstanding commitment to prioritizing the health and safety of donors and patients, contributing to society and the environment while supporting our employees."

GRIFOLS

“Sustainability is and has been at the core of all we do as a company and is therefore also a priority in our agenda for 2030 as we continue to grow and meet evolving changes in society.

“Our efforts are always guided by our strong values and the aim to demonstrate true leadership in our industry and the world we operate in,” said **Thomas Glanzmann, Chairperson of the Grifols’ Board Sustainability Committee.**

Grifols’ strong performance this year was driven largely by its top scores in corporate citizenship and philanthropy, environmental and social reporting, and marketing practices, coupled with the significant improvements recorded in human rights, risk and crisis management and health outcome contribution.

“We have achieved this excellent outcome again thanks to the dedication of Grifols’ employees, who are crucial to making sustainability an essential part of our culture, business model and practices. We are more than ready to continue addressing the defining issues of our time and to respond to the global challenges of climate, health and equity,” said **Nuria Pascual, Vice President and Investor Relations and Sustainability Officer.**

For more information on Grifols’ ESG initiatives and progress, please visit [Sustainability | Grifols](#) and read more about our commitment in [Integrated and Sustainability Annual Report](#).

About the Dow Jones Sustainability Index (DJSI)

The Dow Jones Sustainability Index (DJSI), jointly developed by S&P Dow Jones Index and RobecoSAM, are corporate sustainability evaluation indices for environmental, social and governance (ESG) investment that serve as a benchmark for investors who integrate sustainability considerations into their portfolios and look for best-in-class performance.

The indices have achieved an iconic status as the global standard for measuring and advancing corporate ESG practices. More specifically, the DJSI World targets the top 10% of ESG performers which S&P Global considers key to generating long-term stakeholder value.

To prepare the Dow Jones Sustainability Index, S&P Dow Jones applies a transparent, rules-based constituent selection process based on companies’ S&P Global Corporate Sustainability Assessment (CSA). The CSA consists of an extended questionnaire assessing both public and non-public data submitted by participating companies. This year, more than 10,000 publicly traded companies were invited to participate in the S&P Global CSA.

Grifols Sustainability recognitions

Grifols has been included in the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibex sustainability stock market indices since 2018, and on the Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 indices, based on the Vigeo Eiris assessment, since 2020. Since 2021, Grifols has also been included in the Bloomberg Gender-Equality Index (GEI) in recognition of its commitment to addressing gender inequality.

GRIFOLS

Investor contact:

Investor Relations and Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

Media contacts:

<p>Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com Borja Gómez Borja_gomez@duomocomunicacion.com Duomo Comunicación – Grifols Press Office Tel. +34 91 311 92 89 - 91 311 92 90 +34 659 57 21 85 / +34 650 40 22 25</p>	<p>Grifols Press Office media@grifols.com Tel. +34 93 571 00 02</p>
---	---

About Grifols

Grifols is a global healthcare company which was founded in Barcelona in 1909 and is committed to improving the health and well-being of people around the world. Its three main business units – Biopharma, Diagnostic and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 110 countries.

A pioneer in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 27,000 employees in more than 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2021, Grifols' economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibx-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Spanish Main Market (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.